Leveraging psychedelic therapies for binge eating disorder
Open Access Government July 10, 2023 DOI: 10.56367/oag-039-10936 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psychedelic-assisted psychotherapy |
| Topics | Psilocybin Psychedelic-assisted therapy |
| Keywords | Dosing Eating disorders Hallucinogen Binge-eating disorder Pharmacology Bulimia nervosa |
| Key findings | Intravenous psilocin (TRP-8803) offers more precise dosing than oral psilocybin, potentially improving reproducibility in clinical studies for binge eating disorder. |
Abstract
Leveraging psychedelic therapies for binge eating disorder Here Tryp Therapeutics examine the viability of using psychedelic therapies for Binge Eating Disorder and the potential results that using psychedelic-assisted psychotherapy could have on different eating disorders. Tryp Therapeutics is a clinical-stage biotechnology company dedicated to the development of exclusive and innovative formulations for administering psilocin in conjunction with psychotherapy, aiming to address unmet medical needs in various diseases. Our primary focus is on our lead program, TRP-8803, which represents a proprietary formulation of intravenous (IV) infused psilocin, the active metabolite of psilocybin. This formulation overcomes several limitations associated with oral psilocybin administration. By directly administering psilocin via the intravenous route, we achieve the most precise form of dosing, ensuring the reproducibility of blood levels necessary for clinical efficacy while preserving safety. In contrast, oral administration of psilocybin relies on enzymatic conversion of psilocybin to psilocin, resulting in substantial variability in drug blood levels among patients, potentially confounding the planned outcome of clinical studies.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |